Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease

Blood. 2024 Aug 8;144(6):672-675. doi: 10.1182/blood.2023023028.

Abstract

Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Anemia, Sickle Cell* / complications
  • Anemia, Sickle Cell* / pathology
  • Anemia, Sickle Cell* / therapy
  • Cardiomyopathies / etiology
  • Cardiomyopathies / pathology
  • Cardiomyopathies / therapy
  • Child
  • Child, Preschool
  • Female
  • Fibrosis*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Myocardium / pathology
  • Young Adult

Associated data

  • ClinicalTrials.gov/NCT04362293